Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
In this study, we revealed that a long noncoding RNA, PANDA, induced by oncogenic signal stabilizes p53 tumor suppressor protein in response to DNA damage. Quantitative RT-PCR assay showed that PANDA was highly expressed in U2OS human osteosarcoma cells. Silencing PANDA caused arrest at the G1 phase of the cell cycle, leading to inhibition of cell proliferation. We revealed that PANDA promotes G1-S transition by repressing p18 transcription, and thus promotes U2OS cell proliferation. These results indicate that PANDA may be a good molecular target for cancer treatment drug.
|